- Publicerad
Redeye has a largely neutral take on Nanologica’s Q2 2023 report in terms of the financials. Sales came in below our estimates, but concrete orders materializing remains key for the investment case. We leave our initial comments.
Redeye
Redeye has a largely neutral take on Nanologica’s Q2 2023 report in terms of the financials. Sales came in below our estimates, but concrete orders materializing remains key for the investment case. We leave our initial comments.
Redeye